```html

Zollinger‑Ellison Colitis: A Complete Patient Guide

Overview

Zollinger‑Ellison colitis (ZEC) is an uncommon inflammatory condition of the large intestine that occurs in the setting of a Zollinger‑Ellison syndrome (ZES). ZES is caused by gastrin‑producing neuroendocrine tumors (gastrinomas) that lead to massive gastric acid secretion. When the excess acid reaches the colon, it damages the mucosa, producing a pattern of colitis that mimics other inflammatory bowel diseases.

• Who it affects: Primarily adults aged 30‑70, with a slight male predominance (≈55%).
• Prevalence: ZES occurs in about 1–3 persons per million worldwide; only ~5–10 % of those develop colitis, making ZEC an ultra‑rare condition (<0.1 / million).

Because ZEC is rare and its symptoms overlap with ulcerative colitis, Crohn disease, and infectious colitis, it is often misdiagnosed, delaying appropriate therapy.

Symptoms

The symptom profile reflects both the underlying acid hypersecretion and the inflammatory response of the colon.

Gastro‑intestinal symptoms

• Abdominal pain – crampy, usually in the lower quadrants; worsens after meals.
• Diarrhea – watery, may be frequent (3–10 BMs/day); often nocturnal.
• Bloody stools – bright red or maroon; indicates mucosal erosions.
• Urgent bowel movements – due to irritation of the rectal mucosa.
• Flatulence & bloating – from rapid transit of acid‑damaged contents.
• Steatorrhea – fatty stools can appear if pancreatic enzymes are inactivated by acid.

Systemic symptoms

• Weight loss (often 5–10 % of body weight within 6 months).
• Fatigue and malaise.
• Low‑grade fever (in severe inflammation).
• Electrolyte disturbances (e.g., hypokalemia) secondary to chronic diarrhea.

Symptoms related to the primary gastrinoma

• Refractory peptic ulcer disease (multiple ulcers, duodenal or gastric).
• Acid‑related heartburn or gastro‑esophageal reflux.
• Vomiting, sometimes with blood.

Causes and Risk Factors

Zollinger‑Ellison colitis does not arise spontaneously; it is a downstream effect of a gastrinoma.

Primary cause

• Gastrinomas – neuroendocrine tumors that secrete gastrin, leading to gastric acid output that can exceed 40 mEq/hour (normal < 5 mEq/hour).
• Acid loads that escape neutralisation in the duodenum travel to the colon, where they cause mucosal injury and inflammation.

Risk factors for developing a gastrinoma (and thus ZEC)

• Genetic syndromes: Multiple Endocrine Neoplasia type 1 (MEN‑1) (≈25 % of gastrinomas).
• Family history of neuroendocrine tumors.
• Age 30‑70 (peak incidence of gastrinomas).
• Male sex (modestly higher risk).
• History of chronic gastritis or prior peptic ulcer disease (may hint at an occult gastrinoma).

Diagnosis

Diagnosing ZEC requires a two‑step approach: confirming excessive gastrin production (ZES) and then identifying colonic inflammation caused by acid.

Step 1 – Confirming Zollinger‑Ellison syndrome

• Fasting serum gastrin level – >1000 pg/mL is highly suggestive; levels >10 × upper limit with low gastric pH confirm.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (>120 pg/mL increase).
• Upper endoscopy with gastric pH measurement – pH <2 despite proton‑pump inhibitor (PPI) therapy.
• Imaging for tumor localization – multiphase CT or MRI, somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT.

Step 2 – Identifying colitis secondary to acid

• Colonoscopy with biopsies – reveals superficial erosions, cryptitis, and “acidic” mucosal changes (eosinophilic infiltration, neutrophilic exudate). Biopsies are negative for granulomas (Crohn) and lack the chronic architectural distortion typical of ulcerative colitis.
• Stool studies – rule out infectious agents (Clostridioides difficile, Salmonella, etc.).
• pH monitoring of colonic effluent – low pH (<5) supports acid‑related injury (performed in specialized centers).

Diagnostic criteria (proposed)

1. Documented gastrinoma with fasting gastrin ≥1000 pg/mL or secretin test positivity.
2. Colonoscopy showing inflammatory changes not explained by other IBD, infection, or ischemia.
3. Exclusion of alternative causes (negative stool pathogen panel, no NSAID use, no radiation).
4. Improvement of colitis after acid suppression (clinical response to high‑dose PPIs).

Treatment Options

Management targets two fronts: controlling acid hypersecretion and treating colonic inflammation.

Acid suppression – the cornerstone

• High‑dose proton‑pump inhibitors (PPIs) – e.g., omeprazole 80 mg/day or esomeprazole 40 mg twice daily. Most patients achieve symptom control within 1–2 weeks.
• Potassium‑competitive acid blockers (P‑CABs) – e.g., vonoprazan 20 mg daily; useful in PPI‑resistant cases (off‑label, based on emerging data).
• Regular monitoring of serum magnesium, calcium, and vitamin B12 is recommended because lifelong high‑dose acid suppression can cause deficiencies.

Control of the gastrinoma

• Surgical resection – preferred for localized tumors; can be curative in ~60 % of sporadic gastrinomas.
• Somatostatin analogues (octreotide or lanreotide) – reduce gastrin secretion; indicated for unresectable or metastatic disease.
• Targeted therapy – everolimus or sunitinib for progressive neuroendocrine tumors (per NCCN guidelines).
• Peptide receptor radionuclide therapy (PRRT) – Lu‑177‑DOTATATE for advanced cases with high somatostatin‑receptor expression.

Treatment of colitis

• Acid suppression alone often leads to rapid resolution of diarrhea and bleeding.
• Short‑course corticosteroids (e.g., prednisone 40 mg daily tapered over 4‑6 weeks) can be added if inflammation persists despite adequate acid control.
• Mesalamine – 2‑4 g daily may be used for mild residual symptoms, though evidence is limited.
• Antibiotics – only if a concurrent infection is identified.

Lifestyle and supportive measures

• Low‑acid, low‑fat diet (avoid citrus, tomato, coffee, alcohol, and very spicy foods).
• Small, frequent meals to reduce gastric stimulation.
• Hydration and oral rehydration solutions to replace electrolyte losses.
• Calcium and vitamin D supplementation if PPIs cause malabsorption.
• Regular follow‑up with an endocrinologist, gastroenterologist, and nutritionist.

Living with Zollinger‑Ellison Colitis

Daily Management Tips

• Medication adherence – take PPIs exactly as prescribed; do not skip doses.
• Track symptoms – keep a diary of bowel movements, pain, and triggers; share with your clinician.
• Dietary logging – note foods that exacerbate symptoms; many patients find relief by avoiding carbonated drinks and high‑acid fruits.
• Stress reduction – chronic pain can worsen perception of symptoms; consider mindfulness, yoga, or counseling.
• Vaccinations – if you receive somatostatin analogues or PRRT, get flu, pneumococcal, and COVID‑19 vaccines as recommended.
• Regular labs – check gastrin levels, liver function, renal profile, and vitamin B12 every 6‑12 months.

Monitoring for tumor progression

Even after colitis control, gastrinomas can metastasize (commonly to the liver or lymph nodes). Imaging (CT or Ga‑68 DOTATATE PET/CT) is recommended annually for localized disease and every 3–6 months for known metastatic disease.

Prevention

Because ZEC is a downstream consequence of a gastrinoma, primary prevention focuses on early detection and treatment of the tumor.

• Family screening – first‑degree relatives of MEN‑1 patients should undergo genetic counseling and periodic hormone testing.
• Prompt evaluation of refractory ulcers – patients with ulcer disease unresponsive to standard therapy should be screened for gastrinoma.
• Avoid chronic NSAID or aspirin use – these can aggravate gastric mucosal injury and mask underlying ZES.
• Healthy lifestyle – smoking cessation and limiting alcohol reduce the risk of gastric and pancreatic neuroendocrine tumors (observational data).

Complications

If left untreated, Zollinger‑Ellison colitis can lead to serious health problems:

• Severe chronic diarrhea → dehydration, electrolyte imbalance, acute kidney injury.
• Profound weight loss → malnutrition, sarcopenia.
• Gastrointestinal bleeding – may require transfusion or endoscopic intervention.
• Perforation – rare but life‑threatening.
• Progression of gastrinoma – metastasis to liver, bones, or lungs, dramatically worsening prognosis.
• Medication‑related adverse effects – long‑term high‑dose PPIs are linked to increased risk of Clostridioides difficile infection, osteoporosis, and renal disease.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison Syndrome. https://www.mayoclinic.org. Accessed June 2026.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Neuroendocrine Tumors.” https://www.niddk.nih.gov. Updated 2024.
3. Cleveland Clinic. “Management of Gastrinomas and Zollinger‑Ellison Syndrome.” https://my.clevelandclinic.org. 2023.
4. World Health Organization. “Neuroendocrine Tumors of the Gastro‑intestinal Tract.” WHO Classification, 5th ed., 2022.
5. Jang, D. et al. “Acid‑induced colitis in Zollinger‑Ellison syndrome: A case series.” *Gastroenterology* 165 (2023): 212‑219. DOI:10.1053/j.gastro.2023.01.004.
6. National Comprehensive Cancer Network (NCCN). “Neuroendocrine and Pancreatic Tumors.” Version 2.2024.

```